Bodnar V. A., Koval T. I., Kotelevska T. M., Marchenko O. H., Pryimenko N. O., Syzova L. M., Izyiumska O. M.

CLINICAL CHARACTERISTICS OF PATIENTS WITH SEVERE AND CRITICAL COVID-19

---

Show/Download

About the author:

Bodnar V. A., Koval T. I., Kotelevska T. M., Marchenko O. H., Pryimenko N. O., Syzova L. M., Izyiumska O. M.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The COVID-19 pandemic has caused a significant increase in hospitalizations and deaths, primarily due to pneumonia with multiorgan involvement; however, despite the vaccines and treatments developed, the number of patients with COVID-19 remains high, resulting in a high incidence of severe illness and death. This may also be due to the emergence of new variants of SARS-CoV-2 due to the constant mutation of the virus. The study aimed to characterize the clinical course of severe COVID-19 and identify prognostic markers of disease progression to death. This retrospective study was based on data from 552 patients diagnosed with "acute respiratory disease COVID19" who had a severe/critical course and were treated in the intensive care unit. Demographic, epidemiological, clinical and laboratory characteristics, as well as risk factors at the time of hospitalization were analyzed. Patients with a fatal outcome had a longer period from the first manifestation of the disease to hospitalization in the Department of Reanimation and Intensive Care, more often had dyspnea and dizziness, required invasive mechanical ventilation, and more often had indications for oxygen supply of more than 5 liters. In addition, patients who died from COVID-19 were more likely to suffer from cardiovascular diseases, including grade II hypertension, coronary heart disease and diffuse cardiosclerosis, obesity, and solid organ malignancies; they had lower platelet and lymphocyte counts, higher LDH and creatinine values, and more pronounced signs of hypercoagulability. This study has demonstrated some features of COVID-19 that should be considered to predict the possible progression of the disease to death.

Tags:

Bibliography:

1. Rabaan AA, Smajlović S, Tombuloglu H, Ćordić S, Hajdarević A, Kudić N, et al. SARS-CoV-2 infection and multi-organ system damage: A review. Biomol Biomed. 2023 Feb 1;23(1):37-52. DOI: 10.17305/bjbms.2022.7762.
2. Ufuk F, Savaş R. COVID-19 pneumonia: lessons learned, challenges, and preparing for the future. Diagn Interv Radiol. 2022 Nov;28(6):576- 585. DOI: 10.5152/dir.2022.221881.
3. Zhou A, Song Q, Peng Y, Liao X, Huang P, Liu W, et al. Symptoms at disease onset predict prognosis in COVID-19 disease. Libyan J Med. 2022;17(1):2010338. DOI: 10.1080/19932820.2021.2010338.
4. Izmailova O, Shlykova O, Kabaliei A, Vatsenko A, Ivashchenko D, Dudchenko M, et al. Polymorphism of tmprss2 (rs12329760) but not ace2 (rs4240157), tmprss11a (rs353163) and cd147 (rs8259) is associated with the severity of COVID-19 in the Ukrainian population. Acta Biomed. 2023;94(1):e2023030. DOI: 10.23750/abm.v94i1.13543.
5. Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, et al. Insights for COVID-19 in 2023. Rev Esp Quimioter. 2023 Apr;36(2):114-124. DOI: 10.37201/req/ 122.2022.
6. Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022 Oct 15;29(1):82. DOI: 10.1186/s12929-022-00853-8.
7. Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023 Jan 26;14:1125246. DOI: 10.3389/ fimmu.2023.1125246.
8. Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023 Jun;22(6):449-475. DOI: 10.1038/s41573-023-00672-y.
9. Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, et al. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health. 2023 Jan;16(1):4-14. DOI: 10.1016/j.jiph.2022.11.024.
10. Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: Current insights and future directions. Microbiol Res. 2022 Dec;265:127204. DOI: 10.1016/j.micres.2022.127204.
11. World Health Organization. Tracking SARS-CoV-2 Variants. [cited 2023 Sep 06]. Available from: https://www.who.int/activities/trackingSARS-CoV-2-variants.
12. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. 2022 Apr 26 [cited 2023 Sep 06]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifi cations.html.
13. Tsentr hromadsʹkoho zdorovʺya. Tyzhnevyy zvit pro ryzyky dlya hromadsʹkoho zdorovʺya. [cited 2023 Sep 06]. Dostupno: https://phc.org. ua/ sites/default/files/users/user90/risk_2023_10.pdf. [in Ukrainian]
14. National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection. Last Updated: 2023 March 6 [cited 2023 Sep 06]. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 3, 170, 184-194 pages, index UDC 616.98:578.834-036.17-05

DOI:

10.29254/2077-4214-2023-3-170-184-194